HOME >> BIOLOGY >> NEWS
Nexavar significantly extends overall survival by 44 percent in liver cancer patients

Chicago, IL June 4, 2007 -- Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that Nexavar (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44% (HR=0.69; p-value=0.0006). Results were presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO).

The international, Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial randomized and evaluated 602 liver cancer patients who had no prior systemic therapy at sites in the Americas, Europe, and Australia/New Zealand. The primary objective of the study was to compare overall survival in patients administered Nexavar versus those administered placebo. Median overall survival was 10.7 months in Nexavar-treated patients compared to 7.9 months in those taking placebo.

Because there are no therapies that significantly improve survival for the thousands of patients with liver cancer, these findings demonstrate the compelling study results of Nexavar as the new reference standard of care for the first-line treatment of HCC, said Dr. Josep M. Llovet, co-principal investigator and Professor of Research, Barcelona Clinic Liver Cancer (BCLC) Group, IDIBAPS, Liver Unit, Hospital Clinic Barcelona; Director of Research, HCC Program, Associate Professor of Medicine, Mount Sinai School of Medicine, New York.

Bayer and Onyx halted the SHARP trial in February 2007 when an independent data monitoring committee determined in a pre-scheduled analysis that the overall survival endpoint had been met. There were no significant differences in serious adverse event rates between the Nexavar and placebo-treated groups, with the most commonly observed serious adverse events in patients receiving Nexavar being diarrhea and hand-foot-skin reaction. Based on the strength of the d
'"/>

Contact: Charlotte Rocker
crocker@gcigroup.com
212-537-8290
GCI Group
4-Jun-2007


Page: 1 2 3

Related biology news :

1. Adding folic acid to flour significantly reduces congenital malformations
2. Antibody linked to MS significantly higher in spinal fluid of blacks
3. Herceptin plus chemotherapy significantly increases disease-free survival in breast cancer
4. High HPV concentrations combined with smoking significantly raise risks of cervical cancer
5. Using an activated-carbon filtering pitcher significantly reduces chemicals in tap water
6. Miscarriage significantly associated with increasing paternal age
7. Regular multivitamin use near time of conception significantly reduces preeclampsia risk
8. Children born after abortion ban had significantly better educational achievements
9. Brain changes significantly after age 18, says Dartmouth research
10. New data demonstrate that Benicar and Benicar HCT significantly reduces systolic hypertension
11. Elevated inflammatory enzyme, Lp-PLA2, significantly linked to ischemic stroke

Post Your Comments:
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
(Date:11/7/2014)... November 6, 2014 Leading Biometric companies ... mobile security revolutionizing online transactions.  Companies in focus today are: ... (NYSE: BABA ), Google Inc. (NASDAQ: ... Inc. (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: ... and NXTDW), a biometric authentication company focused on the growing ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
(Date:11/18/2014)... 17, 2014 RPS Diagnostics (RPS®) ... – today announces its third annual partnership of ... Get Smart About Antibiotics Week from November 17-23. ... national campaign designed to highlight the coordinated efforts ... non-profit and for-profit partners to provide education about ...
(Date:11/18/2014)... 18, 2014 American Process Inc. ... formed a partnership with researchers at Georgia Institute ... Technology, and the USDA’s Forest Products Laboratory to ... nanocellulose. Nanocellulose is a rapidly emerging high performance ... project is to replace heavy steel structures within ...
(Date:11/18/2014)... PARK, Calif. , Nov. 18, 2014 /PRNewswire/ ... biotechnology company in the emerging field of regenerative ... program, AST-OPC1 (oligodendrocyte progenitor cells) for complete cervical ... one of ten "Top Advanced Therapies Projects to ... are delighted to receive this significant industry honor, ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 2Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 3
Cached News: